Fact-checked by Grok 2 weeks ago

Atopy

Atopy is a hereditary predisposition to develop (IgE)-mediated reactions to common environmental allergens, leading to a range of allergic conditions including , , and . The term, derived from the Greek word atopia meaning "out of place," was coined in 1923 by American allergists Arthur F. Coca and Robert A. Cooke to describe inherited tendencies toward immediate reactions distinct from other forms of . This predisposition arises from a complex interplay of genetic and environmental factors, with key genetic influences including mutations in the gene that impair skin barrier function and promote penetration. Atopy drives a Th2-biased , characterized by overproduction of IgE antibodies, activation, and release such as interleukin-4 and interleukin-13, which amplify allergic inflammation. Clinically, it manifests as the "atopic march," a progressive sequence where early-onset in infancy often precedes in childhood and in or adulthood. Globally, atopy affects 10% to 30% of individuals in developed countries, with rising attributed to , practices, and dietary changes that alter microbial exposure during critical developmental windows. In children, the lifetime of atopic diseases can reach 20% or higher in industrialized regions, though rates vary by geography—lower in rural or low-income settings but increasing rapidly in emerging economies. Management focuses on avoidance, like antihistamines and topical corticosteroids, and emerging biologics targeting IgE or Th2 pathways, underscoring atopy's role as a foundational driver of allergic morbidity worldwide.

Definition and Overview

Definition

Atopy is defined as a hereditary predisposition to develop (IgE)-mediated reactions to common environmental allergens, such as , mites, and pet dander. This genetic tendency results in an exaggerated characterized by the of specific IgE antibodies against otherwise harmless substances, distinguishing it from non-IgE-mediated allergies. The term "atopy" was coined in 1923 by allergists Arthur F. Coca and Robert Cooke to describe familial tendencies toward certain allergic conditions, emphasizing their inherited nature and separation from infectious or toxic hypersensitivities. A hallmark of atopy is the "atopic march," which refers to the typical sequential progression of allergic manifestations beginning with in infancy, followed by in early childhood, and often culminating in during later childhood or . This progression reflects the underlying predisposition and is observed in a significant proportion of affected individuals, though not all follow the exact sequence. Key characteristics of atopy include an exaggerated T helper 2 (Th2) immune response, which promotes IgE class switching and activation; persistently elevated total serum IgE levels; and positive skin prick tests to common aeroallergens or food allergens, indicating . These features underpin the predisposition to conditions such as and eczema.

Associated Conditions

Atopy is primarily manifested through the core atopic triad of (eczema), (hay fever), and , which share underlying IgE-mediated mechanisms and often present sequentially or concurrently in affected individuals. These conditions exemplify the interconnected nature of atopic disorders, where early-onset frequently precedes the development of respiratory allergies like and in a progression termed the atopic march. Beyond the triad, atopy is associated with other allergic conditions, including food allergies, urticaria, and , which arise from similar dysregulated immune responses to environmental triggers. Food allergies, in particular, often co-occur with and can exacerbate the overall atopic burden. Co-occurrence among atopic conditions is notably high, with studies showing that up to 60% of children with severe progress to , and children with face a sixfold increased of developing food allergies compared to non-atopic peers. Additionally, up to 75% of individuals with exhibit concomitant symptoms, underscoring the multimorbid profile of atopy. A key feature of atopy is polysensitization, wherein affected individuals develop IgE-mediated reactivity to multiple allergen categories, such as aeroallergens (e.g., and dust mites) and foods, heightening the risk of diverse allergic manifestations across organ systems. This phenomenon contributes to the observed clustering of conditions and emphasizes the systemic predisposition in atopic individuals.

Clinical Presentation

Signs and Symptoms

Atopic conditions, which encompass a predisposition to allergic , commonly manifest with intense pruritus (itching) as a hallmark symptom, often leading to recurrent exacerbations that flare in response to triggers such as allergens or irritants. Patients frequently report a personal or family history of atopy, reflecting the hereditary nature of these disorders, though this is more indicative of underlying susceptibility than an acute sign. These symptoms vary by the specific atopic disease but share a pattern of affecting , , or both. In atopic dermatitis, the primary presentation involves dry, eczematous rashes that appear as red, inflamed patches, particularly on the face, flexures, and extremities in infants and children, accompanied by severe itching that worsens at night. Allergic typically features wheezing, , (often nocturnal), and chest tightness, which may be episodic and triggered by exposure to allergens like or dust mites. Allergic , meanwhile, is marked by sneezing, clear , , and itchy eyes or throat, with symptoms peaking seasonally or perennially depending on exposure. The atopic march describes a common progression where symptoms often begin with skin involvement in early childhood, such as in infancy, followed by the development of allergies, , and in later years, with studies showing that approximately one-third develop , about 35% develop allergies, and up to 45% develop . However, the atopic march is not observed in all cases, and its existence as a linear progression remains a topic of ongoing research and debate. This sequential pattern underscores the interconnected nature of atopic manifestations. Complications arising from these symptoms include sleep disturbances due to unrelenting pruritus or nocturnal wheezing, which can impair daily functioning and growth in children. Secondary bacterial infections, such as those from , frequently occur from scratching-induced skin breakdown in . Overall, these conditions substantially reduce , contributing to psychological distress, social limitations, and decreased productivity across all ages.

Diagnosis

Diagnosis of atopy relies primarily on a thorough clinical history that identifies a personal or family history of atopic diseases, such as , , or , along with IgE-mediated symptoms triggered by common environmental allergens like , house dust mites, or animal dander. This history helps establish the and pattern of immediate reactions characteristic of atopy. Laboratory evaluations support the clinical assessment through measurement of total serum IgE levels, which are frequently elevated in atopic individuals, reflecting heightened IgE production. Allergen-specific IgE testing, performed via (RAST) or ImmunoCAP assays, detects to particular allergens by quantifying IgE antibodies in serum, with levels above 0.35 kUA/L typically indicating positivity. Peripheral blood counts are also assessed, as often accompanies atopic conditions due to allergic . Skin prick testing serves as a frontline method for confirming IgE-mediated , involving the application of standardized extracts to the volar or back, followed by a gentle prick or puncture with a to introduce the into the . After 15-20 minutes, the response is interpreted by measuring the wheal (indurated area) diameter; a wheal greater than 3 mm larger than the negative is generally considered positive, indicating clinical when correlated with . Limitations include potential false-positive reactions in patients with dermographism, where non-specific skin reactivity mimics allergic responses, necessitating careful interpretation and sometimes withdrawal prior to testing. Emerging diagnostic tools enhance precision in identifying atopy. Component-resolved diagnostics (CRD) employs recombinant or purified components to measure IgE reactivity to specific molecular epitopes, enabling differentiation between true allergies and cross-reactivities for more targeted management. Genetic testing for loss-of-function mutations in the (FLG) gene identifies individuals at higher risk for by detecting impaired skin barrier function, though it is not routinely used for all cases but rather in severe or familial presentations. Differential diagnosis involves ruling out non-IgE-mediated conditions to confirm atopic etiology, such as , which presents with similar eczematous lesions but lacks allergen-specific IgE and history of atopy, or intrinsic , characterized by airway without demonstrable to airborne allergens. These distinctions are guided by the absence of positive prick or specific IgE tests in non-atopic mimics.

Pathophysiology

Immune Mechanisms

Atopy is characterized by a reaction, an immediate IgE-mediated triggered by exposure in sensitized individuals. Upon re-exposure to the , IgE antibodies bound to high-affinity FcεRI receptors on mast cells and cross-link, leading to rapid and release of preformed mediators such as , as well as newly synthesized lipid mediators like leukotrienes and prostaglandins, and cytokines including TNF-α. This cascade initiates acute symptoms like , increased , and smooth muscle contraction, while also promoting chronic through recruitment of additional immune cells. Central to atopic immune responses is the differentiation of CD4+ T helper cells into Th2 cells, predominantly driven by cytokines IL-4 and IL-13 produced by innate lymphoid cells type 2 (ILC2s) and early Th2 cells. IL-4 signals through the IL-4Rα/γc receptor complex, activating STAT6 to promote Th2 lineage commitment from naïve T cells, while both IL-4 and IL-13 induce B-cell class switching to IgE production via similar STAT6-dependent pathways in germinal centers. This Th2 bias amplifies IgE synthesis and sustains allergic inflammation, with IL-13 further contributing to tissue remodeling and mucus hypersecretion in affected sites. Impaired function of regulatory T cells (Tregs), particularly + + Tregs, impairs suppression of Th2 responses in atopic individuals, leading to unchecked allergic . Tregs normally inhibit Th2 and production through mechanisms like CTLA-4-mediated suppression of antigen-presenting cells and of s such as IL-10 and TGF-β; however, reduced Treg numbers or function in atopics fails to restore to harmless allergens. This imbalance is evident in lesional and airways, where diminished Treg activity correlates with exacerbated Th2-driven . Epigenetic modifications, particularly DNA methylation changes, contribute to the Th2-biased immune profile in atopy by altering in immune cells. Hypermethylation of Th1-associated loci and hypomethylation of Th2 genes in T cells and B cells promote sustained Th2 and IgE class switching, often established early in life or influenced by environmental exposures. These stable epigenetic marks, including modifications, reinforce the atopic across generations and tissues. Key cytokines and immune cells further orchestrate atopic responses: IL-5, secreted by Th2 cells and ILC2s, drives maturation, survival, and activation in and tissues, amplifying tissue and damage through release of cytotoxic granule proteins like major basic protein. , activated via IgE cross-linking, serve as rapid sources of IL-4 and IL-13, enhancing Th2 polarization and recruiting other effectors early in allergic reactions. Dendritic cells, particularly those expressing CD1a in the skin, present s to naïve T cells via MHC II and co-stimulatory molecules, priming Th2 differentiation through production of IL-4-inducing factors like TSLP and OX40L. These interactions, while influenced by barrier defects that facilitate entry, underscore the core immunological dysregulation in atopy.

Barrier Dysfunction

Barrier dysfunction in atopy refers to structural defects in epithelial tissues that compromise their protective role, allowing environmental allergens and irritants to penetrate more easily and initiate or sustain allergic responses. In the skin, mutations in the gene (FLG) represent a key to impaired barrier integrity, resulting in reduced filaggrin protein expression that disrupts the 's lipid matrix and process. This leads to increased (TEWL), a hallmark of dry and vulnerable skin in , where TEWL levels are often elevated even in non-lesional areas compared to healthy controls. Non-invasive assessments, such as TEWL measurement using evaporimeters and corneometry to quantify hydration, provide objective quantification of these defects and correlate with disease severity. In respiratory and mucosal barriers, atopy involves diminished expression of tight junction proteins, including claudins (e.g., claudin-1 and claudin-7) and occludins, which seal intercellular spaces in airway and nasal epithelia. These reductions, observed in conditions like and , increase epithelial permeability, enabling to access subepithelial immune cells and trigger . Consequences of such barrier impairments across epithelial sites include heightened allergen sensitization through direct to dendritic cells, predisposition to microbial superinfections due to easier pathogen ingress (e.g., colonization in atopic skin), and perpetuation of chronic inflammation via sustained exposure to triggers. This interplay forms a vicious cycle, wherein initial barrier defects promote that further degrades epithelial integrity, thereby maintaining the atopic state over time. Th2 cytokines, such as IL-4 and IL-13, contribute to this by downregulating proteins and expression.

Etiology

Genetic Factors

Atopy, characterized by an exaggerated IgE-mediated to allergens, exhibits a strong genetic basis through polygenic , where multiple genes each contribute small effects to susceptibility. estimates for atopic traits, including (AD), , and , range from 50% to 80%, derived from family and twin studies that highlight the substantial genetic influence on development. Family studies, particularly twin concordance analyses, provide robust evidence for this . Monozygotic twins show significantly higher concordance rates for atopic conditions compared to dizygotic twins; for instance, pairwise concordance for reaches 0.72 in monozygotic pairs versus 0.23 in dizygotic pairs, underscoring the role of shared over environmental factors alone. Similar patterns hold for and other atopic diseases, with monozygotic concordance typically ranging from 20% to 50% in population-based cohorts. Among key genes implicated in atopy, loss-of-function mutations in the gene (FLG) on 1q21 represent the strongest for impaired , predisposing individuals to and secondary allergic . Cytokine-related genes such as IL4 and IL13 on 5q31 promote Th2 immune skewing and IgE production, enhancing susceptibility to allergic inflammation across atopic disorders. Additionally, ADAM33 on 20p13 contributes to airway remodeling in , influencing through its role in activity. Genome-wide association studies (GWAS) have further delineated these polygenic contributions, identifying susceptibility loci such as the 17q21 region harboring ORMDL3, which regulates sphingolipid biosynthesis and is strongly linked to childhood-onset . The seminal GWAS by Moffatt et al. (2007) demonstrated that variants near ORMDL3 increase asthma risk by upregulating in airway epithelial cells, with odds ratios up to 1.5 in pediatric cohorts. These findings have been replicated across diverse populations, confirming the locus's role in early-life atopy. Epistatic interactions, including gene-environment effects, modulate atopic risk; for example, FLG mutations exacerbate skin barrier dysfunction and AD severity in low-humidity environments, where reduced moisture impairs filaggrin processing and increases . Such interactions highlight how genetic variants interact with external conditions to influence disease .

Environmental Triggers

Environmental triggers play a pivotal role in provoking or exacerbating atopy by interacting with genetic predispositions, leading to and immune dysregulation in susceptible individuals. Among these, common allergens act as primary sensitizers, initiating IgE-mediated responses that underpin atopic conditions such as , , and . House dust mites (HDM), particularly species like Dermatophagoides pteronyssinus and D. farinae, are ubiquitous indoor allergens whose fecal pellets and body fragments contain potent proteins (e.g., Der p 1 and Der f 1) that penetrate airway and barriers, promoting Th2-skewed and in early life. from trees (e.g., ), grasses (e.g., ), and weeds (e.g., ) serves as a key outdoor allergen, triggering seasonal exacerbations of and through and mucosal exposure, with sensitization rates varying by geographic region and exposure intensity. dander from cats (Fel d 1) and dogs (Can f 1) represents another major indoor sensitizer, with proteins adhering to surfaces and persisting in environments, increasing the risk of perennial allergic symptoms in atopic children and adults. Food allergens, such as (Ara h 1–3), exemplify ingested sensitizers that can provoke systemic reactions; early environmental exposure via or airway routes, as in dust, heightens the likelihood of in those with impaired barriers. Irritants and pollutants further aggravate atopy by directly damaging epithelial barriers and amplifying inflammatory responses, particularly in the airways. , both active and secondhand, contains over 4,000 chemicals that irritate mucous membranes, significantly increasing the of by 20% to 85% in exposed children through enhanced and reduced lung function. , including fine (PM2.5) from vehicle emissions and industrial sources, penetrates deep into the lungs, promoting and Th2 production, with long-term exposure linked to a 30% attributable fraction of cases in urban populations. Occupational exposures to irritants like diisocyanates in or in healthcare settings constitute a significant , accounting for 5–15% of adult cases and often leading to work-exacerbated atopy through repeated and . Microbiome dysbiosis emerges as a critical , where reduced early-life exposure to diverse microbes disrupts and fosters atopic predisposition. The posits that diminished contact with commensal bacteria due to modern , use, and living impairs the development of regulatory T cells, elevating atopy risk in low-exposure cohorts. Early-life factors such as cesarean delivery or formula feeding alter composition, reducing diversity (e.g., lower levels) and correlating with subsequent and eczema onset, as evidenced in prospective birth cohorts. In atopic dermatitis, colonization by exacerbates disease through toxin-mediated mechanisms that amplify Th2-driven inflammation. This bacterium, prevalent on 60–100% of lesional skin in affected patients, produces superantigens like staphylococcal enterotoxin B (SEB) and (TSST-1), which bypass normal to polyclonally activate T cells, boosting IL-4 and IL-13 production while suppressing . These superantigens also induce IgE-specific responses against self-superantigens, perpetuating a cycle of barrier breakdown and chronic inflammation in atopic skin. Emerging climate and lifestyle factors contribute to atopy by modulating immune and barrier integrity. Urbanization correlates with higher atopic disease prevalence, attributed to increased exposure and reduced microbial diversity compared to rural settings, with urban children showing 1.5–2 times greater risk of and eczema. , often stemming from limited sunlight in urban or indoor lifestyles, impairs antimicrobial defense and Th2 regulation, associating with worsened severity in up to 80% of deficient pediatric cases. Diets low in omega-3 polyunsaturated fatty acids (e.g., from ), common in patterns, promote pro-inflammatory eicosanoids, elevating atopic risk; maternal omega-3 supplementation during reduces offspring eczema incidence by 20–30%.

Epidemiology

Prevalence Patterns

Atopy, characterized by a hereditary predisposition to produce (IgE) antibodies in response to common allergens, affects an estimated 10-30% of the population in developed countries. This encompasses a range of allergic conditions, including , which has a of 10-20% among children worldwide. The burden is particularly notable in pediatric populations, where atopic sensitization—evidenced by positive skin prick tests or elevated specific IgE—manifests early and influences the development of multiple allergic phenotypes. Demographic patterns reveal variations by sex, with showing a higher in females, especially post-puberty, due to hormonal influences on immune responses. Socioeconomic disparities may play a role, though findings are mixed and vary by region and access to healthcare. Age distribution demonstrates a peak in childhood, where reaches 10-20% in individuals under 18 years, reflecting the early onset of atopic manifestations. Many cases of show partial resolution during , with symptoms diminishing in 30-70% of affected youth as immune maturation occurs. For , remission occurs in approximately 40-70% by school age or . Regional variations highlight higher prevalence in developed countries, such as where up to 40% of children exhibit atopic sensitization. In contrast, developing regions report lower rates, though these are rising in urbanizing areas. Approximately 50% of individuals with atopy experience multiple comorbid conditions, including combinations of , , and , amplifying overall . Increasing trends in prevalence have been linked to lifestyle changes, such as and dietary shifts. Since the , the prevalence of atopic diseases has risen substantially in Western countries, often doubling or more over several decades. For instance, in the , the prevalence of reported wheeze among children increased from approximately 9.8% in 1973 to 19.7% by 2003, reflecting a near doubling that aligns with broader trends in childhood and atopy. This escalation has been attributed to and environmental shifts in industrialized settings, contributing to a global recognition of atopy as an emerging concern. Following the onset of the in 2020, trends in high-income countries showed signs of stabilization or slight declines in atopic prevalence, particularly during lockdowns. Reduced and limited exposure to respiratory infections were key factors, as lockdowns curtailed outdoor activities and urban emissions in regions like and parts of . For example, atopic prevalence among Korean adolescents declined notably post-2020, with studies linking this to decreased environmental triggers. These temporary shifts highlight the role of modifiable exposures in modulating atopy rates, though long-term stabilization remains under investigation. As of 2021, global atopic cases reached 129 million, with projections indicating continued increases in low- and middle-income countries by mid-century. Several hypotheses explain these temporal patterns. The posits that diminished early-life exposure to microbes in sanitized, urban environments promotes a , favoring allergic over . This theory, supported by lower atopy rates in less hygienic settings, suggests that reduced microbial diversity impairs regulatory T-cell development and immune balance. Complementing this, the dual exposure hypothesis differentiates routes of contact: high-dose oral exposure in early infancy induces , while low-dose cutaneous exposure through compromised skin barriers leads to and atopy. Additionally, shifts toward Western diets—characterized by high processed food intake and low fiber—have been linked to rising atopy, as they alter and exacerbate inflammatory Th2 pathways. Looking ahead, atopy prevalence is projected to continue increasing in low- and middle-income countries, driven by rapid that mirrors Western lifestyle changes. Urban migration exposes populations to higher levels, dietary shifts, and reduced microbial diversity, potentially elevating rates of and by mid-century. These trends underscore the need for targeted monitoring in transitioning economies to mitigate future burdens.

Management

Prevention Strategies

Primary prevention strategies for atopic diseases focus on interventions during pregnancy and early infancy to reduce the risk of onset in genetically susceptible individuals. Exclusive for at least 4 to 6 months is recommended, as it has been associated with a reduced incidence of in children under 2 years and early wheezing under 4 years. Maternal avoidance of common allergens such as cow's milk, eggs, or during or lactation is not advised, as systematic reviews indicate it does not significantly lower the risk of atopic eczema or other atopic conditions in offspring and may pose nutritional risks to the mother and . Early supplementation with , particularly strains like Lactobacillus rhamnosus, shows potential in reducing the incidence of , with meta-analyses reporting a statistically significant preventive effect when administered to mothers during and to infants postnatally. For high-risk infants—those with severe eczema or —early introduction of peanuts between 4 and 11 months of age, as demonstrated by the Learning Early About (LEAP) , substantially lowers the risk of developing , with an 81% relative reduction observed compared to avoidance. Environmental controls in the home environment are also emphasized to minimize early exposures. Avoiding exposure is critical, as during and infancy increases the odds of and other allergic sensitization. Measures to reduce indoor allergens, such as using mite-proof bedding covers to limit exposure, are commonly recommended, though randomized trials indicate they do not significantly decrease the primary incidence of . Public health measures play a role in broader prevention by addressing modifiable environmental factors that exacerbate atopic trends. Regulations to reduce , including and , could prevent a substantial proportion of cases, with estimates suggesting up to 16% of late-life eczema attributable to poor air quality in high-pollution areas. programs, such as those involving bacille Calmette-Guérin (BCG) in , have been linked to a lower risk of atopic diseases in developed countries, potentially by modulating immune responses. Secondary prevention targets infants already showing signs of atopy to interrupt the "atopic march" toward more severe manifestations like or . Proactive use of moisturizers from birth in high-risk infants supports skin barrier function; a showed a reduction in the incidence of by approximately 50% during the application period, though meta-analyses indicate more modest effects (~36% up to 6 months) and long-term effects on the full atopic march require further study. Guidelines from organizations like the American Academy of Allergy, Asthma & Immunology (AAAAI) recommend screening families with a history of atopy—such as , , or in parents or siblings—to identify infants at elevated risk for food allergies and other atopic conditions, prompting targeted interventions like early introduction.

Treatment Options

Treatment of atopic conditions primarily involves a stepwise approach tailored to the specific manifestation—such as , , or —and disease severity, focusing on symptom control and quality of life improvement. Updated 2024-2025 guidelines from the (AAD) and AAAAI emphasize personalized stepwise management, incorporating recent approvals for additional inhibitors and biologics. Allergen avoidance forms the cornerstone of initial management, emphasizing environmental modifications to reduce exposure to triggers like dust mites, pet dander, and . Strategies include using high-efficiency particulate air () filters in vacuums and air purifiers to capture airborne , which has been shown to decrease respiratory symptoms in atopic individuals by reducing indoor particle levels. For food-related atopy, supervised dietary elimination diets may be recommended under medical guidance to identify and avoid specific , though broad eliminations are discouraged due to nutritional risks. Preventive measures, such as consistent barrier protection, can complement these avoidance tactics to enhance overall efficacy. Pharmacotherapy addresses acute and chronic symptoms through targeted agents suited to the atopic condition. In atopic dermatitis, topical corticosteroids remain the mainstay for inflammation control, often combined with emollients to restore barrier function and reduce flare frequency. For , short-acting inhaled beta-agonists provide rapid bronchodilation during exacerbations, while inhaled corticosteroids offer long-term anti-inflammatory effects to prevent progression. , particularly second-generation H1-blockers, are first-line for allergic rhinitis to alleviate sneezing, itching, and by blocking histamine-mediated responses. Biologic therapies represent advanced options for moderate-to-severe cases unresponsive to conventional treatments, targeting key immune pathways. , a inhibiting interleukin-4 and interleukin-13 signaling, is approved for and severe , achieving significant symptom reduction and skin clearance in clinical trials. , an anti-IgE , is particularly effective for allergic with high IgE levels, reducing exacerbation rates and dependence. These agents are administered via subcutaneous injection and are reserved for patients with documented atopy and inadequate response to standard . Allergen-specific () offers disease-modifying potential through gradual desensitization to . Subcutaneous immunotherapy (SCIT) involves escalating doses of allergen extracts injected over 3-5 years, while sublingual immunotherapy (SLIT) uses daily oral tablets or drops for convenience. Both forms have demonstrated long-term efficacy, with studies reporting 20-30% sustained symptom reduction and decreased medication use in respiratory atopy. As of 2025, emerging therapies expand options for refractory , including (JAK) inhibitors like , an oral agent that blocks JAK1 to interrupt signaling and achieve rapid relief and skin improvement in moderate-to-severe cases. Microbiome-based approaches, such as topical or fecal microbiota transplantation, aim to restore dysbiotic skin or gut communities, showing preliminary promise in reducing inflammation and overgrowth in early trials. These innovations underscore ongoing shifts toward personalized, pathway-specific interventions.

References

  1. [1]
    Atopy - StatPearls - NCBI Bookshelf
    Jun 8, 2024 · Atopy is a predisposition to immunological responses against a range of antigens or allergens, leading to CD4+ Th2 differentiation and ...
  2. [2]
    The Atopic March: Critical Evidence and Clinical Relevance - PMC
    Introduced by the American allergists A.F. Coca and R.A. Cooke in 1923, the term “atopy” became closely associated with the immunoglobulin (Ig) E molecule ...Missing: origin | Show results with:origin
  3. [3]
    Epidemiology and natural history of atopic diseases - PMC - NIH
    Mar 24, 2015 · The word atopy (Greek: atopia, out of place) refers to an inherited tendency to produce immunoglobulin E (IgE) antibodies in response to small ...<|control11|><|separator|>
  4. [4]
    Atopy - an overview | ScienceDirect Topics
    Historically, atopy was first described by Coca and Cooke in their 1923 article on the classification of hypersensitive phenomena. The term as they introduced ...
  5. [5]
    Overview of Allergic and Atopic Disorders - Merck Manuals
    Atopy is an exaggerated IgE-mediated immune response; all atopic disorders are type I hypersensitivity disorders. Allergy is any exaggerated immune response ...
  6. [6]
    The history of atopic dermatitis - PubMed
    Fred Wise (1881-1950) and Marion Sulzberger (1895-1983) are often credited with introducing the term atopic dermatitis to dermatology in 1933.
  7. [7]
    The Atopic March: Progression from Atopic Dermatitis to Allergic ...
    The development of atopic dermatitis (AD) in infancy and subsequent allergic rhinitis and asthma in later childhood is known as the atopic march.
  8. [8]
    Revisiting the Atopic March Current Evidence - ATS Journals
    The concept of the atopic march was originally proposed to describe the typical sequence of progression of childhood allergic disorders, with atopic ...
  9. [9]
    Th2 Cytokines and Atopic Dermatitis - PMC - PubMed Central - NIH
    In this review, we highlight the importance of allergic Th2 responses in the development of the disease and summarize relevant literature.
  10. [10]
    Atopy Defined | AAAAI
    Atopy refers to the genetic tendency to develop allergic diseases such as allergic rhinitis, asthma and atopic dermatitis (eczema).
  11. [11]
    The atopic march: current insights into skin barrier dysfunction and ...
    For example, the “allergic triad” – atopic dermatitis (eczema), allergic rhinitis, and allergic asthma – frequently presents in a single individual (3, 4).
  12. [12]
    The Atopic March: Progression from Atopic Dermatitis to Allergic ...
    AD is also part of a process called the atopic march, a progression from AD to allergic rhinitis and asthma. This has been supported by multiple cross-sectional ...
  13. [13]
    Eosinophilic Esophagitis From an Allergy Perspective - NIH
    The majority of patients with EoE have been found to have concomitant allergic conditions, such as asthma, rhinitis, IgE-mediated food allergy, urticaria, and/ ...
  14. [14]
    Food Allergy in Atopic Dermatitis - PMC - NIH
    Food allergy can exacerbate atopic dermatitis and hence routine diet elimination would decrease the severity of AD.
  15. [15]
    Types of sensitization to aeroallergens: definitions, prevalences and ...
    May 1, 2014 · Polysensitization develops over time and is a risk factor for respiratory allergy (being associated with disease severity) and therefore has clinical relevance ...
  16. [16]
    Atopic Dermatitis: A Review of Diagnosis and Treatment - PMC
    Dec 9, 2024 · Atopic dermatitis, more commonly known as atopic eczema, is a chronic, relapsing inflammatory skin disorder characterized by dry skin, localized erythematous ...
  17. [17]
    Atopic Dermatitis - StatPearls - NCBI Bookshelf - NIH
    Atopic dermatitis is seen in approximately 10% to 30% of children and 2% to 10% of adults in developed countries. This prevalence has increased two to three- ...
  18. [18]
    Asthma - StatPearls - NCBI Bookshelf
    May 3, 2024 · The 4 cardinal symptoms associated with asthma are wheezing, cough (often worse at night), shortness of breath, and chest tightness. Individuals ...
  19. [19]
    Allergic Rhinitis - StatPearls - NCBI Bookshelf
    Allergic rhinitis (AR) is an atopic disease characterized by symptoms of nasal congestion, clear rhinorrhea, sneezing, postnasal drip, and nasal pruritis.
  20. [20]
    Atopic Dermatitis: Disease Features, Therapeutic Options, and a ...
    Jun 20, 2023 · Aside from eczema, the main symptom of AD is severe itching, which greatly affects patients' daily activities, productivity, and sleep, reducing ...
  21. [21]
    Atopic Dermatitis: Diagnosis and Treatment - AAFP
    May 15, 2020 · Atopy (personal or family history) Early age at onset. Immunoglobulin E reactivity. Xerosis. Associated features: suggestive of the diagnosis ...
  22. [22]
    Atopic Dermatitis - The New England Journal of Medicine
    Mar 24, 2021 · Diagnosis ; Atopy, Personal or family history or both, IgE reactivity (elevated total or allergen-specific serum IgE or both, seen in up to 80% ...Atopic Dermatitis · Clinical Features · Pathogenesis<|separator|>
  23. [23]
    Phenotype of Atopic Dermatitis Subjects with a History of Eczema ...
    The DACI laboratory performed the following tests on serum samples from all ADEH+ and ADEH- subjects: total IgE (kU/L) and allergen-specific Phadia ImmunoCAP® ...
  24. [24]
    Clinical Evaluation of Techniques for Measuring Nasal-Specific ...
    Oct 20, 2017 · Serum-specific IgE concentrations ≥ 0.35 kIU/L were considered positive. Peripheral blood total eosinophil counts were checked using an ...Missing: laboratory RAST
  25. [25]
    Allergy Testing - StatPearls - NCBI Bookshelf
    Jul 24, 2023 · The other forms of allergy testing do not require specimen collections. Go to: Procedures. Skin Prick Testing. Concentrations of 1 to 10 or 1 to ...
  26. [26]
    Skin prick/puncture testing in North America: a call for standards and ...
    Sep 2, 2014 · The prick/puncture method of skin testing is one that has been ... The skin prick test in the diagnosis of atopic allergy. J Am Acad ...
  27. [27]
    Overview of component resolved diagnostics - PubMed
    Component-resolved diagnostics (CRD) utilize purified native or recombinant allergens to detect IgE sensitivity to individual allergen molecules.Missing: atopy | Show results with:atopy
  28. [28]
    Precision medicine in the allergy clinic: the application of ... - PubMed
    Feb 12, 2022 · Component-resolved diagnosis (CRD) has solved most of the limitations of extract-based diagnostic procedures and is currently valuable tool for the precision ...
  29. [29]
    Filaggrin gene mutations with special reference to atopic dermatitis
    Mutations in the Filaggrin gene can cause absent or reduced filaggrin protein, leading to impaired keratinization and skin barrier defect.Missing: diagnosis | Show results with:diagnosis
  30. [30]
    The persistence of atopic dermatitis and Filaggrin mutations in a US ...
    Filaggrin loss-of-function mutations (FLG null) have been associated with an increased risk of developing AD.
  31. [31]
    Novel diagnostic approaches and biological therapeutics for intrinsic ...
    Jul 8, 2014 · Reviews the diagnostic approach to so-called intrinsic asthma, and evaluates the role of new biological therapies according to the atopy status of asthma.Missing: differential | Show results with:differential
  32. [32]
    Type I Hypersensitivity Reaction - StatPearls - NCBI Bookshelf - NIH
    Aug 3, 2025 · Type I or immediate hypersensitivity is an exaggerated immunoglobulin E (IgE)-mediated immune response to allergens such as pollen, dust ...
  33. [33]
    IgE and mast cells in allergic disease - PMC - PubMed Central
    In this review, we discuss findings supporting the conclusion that IgE and mast cells can have both interdependent and independent roles in the complex immune ...
  34. [34]
    Type I Hypersensitivity Reaction - PubMed
    Aug 3, 2025 · Upon reexposure, the allergen cross-links bound IgE, triggering degranulation and the release of inflammatory mediators. Clinical symptoms vary ...
  35. [35]
    The differential expression of IL-4 and IL-13 and its impact on type-2 ...
    This review summarizes the literature surrounding the function and expression of IL-4 and IL-13 in CD4+ T cells and innate immune cells.
  36. [36]
    Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative ...
    Feb 10, 2025 · IL-4 is critical in Th2 cell differentiation, IgE class switching, and the promotion of chronic pruritus makes it a more comprehensive target ...
  37. [37]
    Type 2 immunity in the skin and lungs - PubMed - NIH
    The present review aims to highlight recent advances in type 2 immunity and discuss the cellular sources, targets, and roles of type 2 mechanisms in asthma and ...
  38. [38]
    Control of Th2-Mediated Inflammation by Regulatory T Cells - PMC
    There is growing evidence that Tregs play an important role in inhibiting Th2-mediated responses to allergens and maintaining immune tolerance. Studies in mouse ...
  39. [39]
    The Role of Regulatory T cells in Atopic Dermatitis - PMC - NIH
    Regulatory T cells (Tregs) play a pivotal role in immune suppression and are integral to the control of allergic responses.
  40. [40]
    T-cell Subset Regulation in Atopy - PMC - PubMed Central - NIH
    Th2-derived IL-4 and IL-13 exert an important role in class switching in B lymphocytes that results in IgE production. Recent evidence on T-cell subset ...
  41. [41]
    DNA methylation of Th2 lineage determination genes at birth is ...
    There is now increasing evidence that asthma and atopy originate in part in utero, with disease risk being associated with the altered epigenetic regulation ...
  42. [42]
    Current understanding of epigenetics in atopic dermatitis - PMC - NIH
    Here, we review our current understanding of epigenetics associated with atopic dermatitis. We discuss studies identifying distinct DNA methylation changes.
  43. [43]
    Genetic and Epigenetic Aspects of Atopic Dermatitis - PMC - NIH
    Recent studies point to the key role of epigenetic changes in the development of the disease. Epigenetic modifications are mainly mediated by DNA methylation, ...
  44. [44]
    Interleukin-5 and IL-5 receptor in health and diseases - PMC
    Overexpression of IL-5 in vivo significantly increases eosinophils and B cells in number, while mice lacking a functional gene for IL-5 or IL-5 receptor display ...
  45. [45]
    Insight into IL-5 as a Potential Target for the Treatment of Allergic ...
    IL-5 has significant effects on allergy and asthma due to its role in eosinophile proliferation and differentiation, which have been well documented [2,4]. To ...
  46. [46]
    Basophils as Key Regulators of Allergic Inflammation and Th2-type ...
    Basophils are Major Sources of IL-4 and IL-13 and are Recruited to Tissues affected by Allergic Inflammation. Basophils express a wide variety of chemokine ...Figure 1 · Basophils Regulate... · Basophils As Targets For...
  47. [47]
    Current and Emerging Strategies to Inhibit Type 2 Inflammation in ...
    Type 2 immune mechanisms, together with mediators such as histamine and prostaglandins, induce a coordinated response of epithelia, sensory neurons, and smooth ...Immune Response And... · Immune Pathways And Their... · Atopic Dermatitis
  48. [48]
    Pathobiology and Regulation of Eosinophils, Mast Cells, and ...
    Apr 16, 2025 · The Th2 cytokines GM‐CSF, IL‐3, and IL‐5 highly regulate the migration and accumulation of eosinophils, basophils, and mast cells, all of which ...
  49. [49]
    Filaggrin and beyond: New insights into the skin barrier in atopic ...
    It is characterized by a dysfunctional skin barrier, which facilitates sophisticated interplay between genetic, immune, microbial, and environmental factors.
  50. [50]
    Skin barrier dysfunction measured by transepidermal water loss at 2 ...
    Recent studies of high-risk atopic individuals showed that a raised TEWL may precede the clinical manifestation of AD in those at high risk of atopy. A defect ...
  51. [51]
    Nonlesional skin in atopic dermatitis is seemingly healthy skin - NIH
    Mar 5, 2013 · Noninvasive bioengineering methods such as TEWL measurement, corneometry, erythema measurement and HF-USG were performed within active ...
  52. [52]
    Claudin-1 Mediated Tight Junction Dysfunction as a Contributor to ...
    Jun 29, 2022 · Tight junctions of the airway epithelium include occludin, claudins, ZOs, and JAMs, which regulate the permeablity of epithelial barrier.
  53. [53]
    Reduced occludin and claudin-7 expression is associated ... - Nature
    Jan 13, 2021 · These results suggest that defective nasal epithelial barrier in AR patients is attributable to reduced expression of OCLN and CLDN7 associated with urban ...
  54. [54]
    Epidermal barrier dysfunction and cutaneous sensitization in atopic ...
    Recent findings have shown that disruption of epithelial barrier systems are involved in the pathogenesis of immune disorders such as inflammatory bowel ...
  55. [55]
    Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive ...
    Jul 5, 2016 · It is a chronic inflammatory skin disease complicated by recurrent bacterial and viral infections that, when left untreated, can lead to significant ...Missing: consequences | Show results with:consequences
  56. [56]
    Skin Barrier Abnormalities and Immune Dysfunction in Atopic ... - MDPI
    Apr 20, 2020 · Filaggrin mutation leads to loss of skin barrier function and an increase in the ILC2 population, promoting acute skin inflammation and the ...Skin Barrier Abnormalities... · 2. Skin Barrier Formation... · 3. Skin Barrier...<|control11|><|separator|>
  57. [57]
    Type 2 immunity in allergic diseases | Cellular & Molecular ... - Nature
    Feb 17, 2025 · Type 2 immunity and eosinophilic esophagitis​​ The disease prominently features a Th2 immune response. EoE strongly correlates with allergies, ...
  58. [58]
    Genetics in Atopic Dermatitis: Historical Perspective and Future ...
    These data demonstrate that the genetic contribution to the development of AD is substantial and this heritability has been estimated at 70–80% (10, 11) – a ...Missing: polygenic | Show results with:polygenic
  59. [59]
    Shared Genetic Architecture Between Atopic Dermatitis and ... - MDPI
    ... factors [3]. The disease displays significant heritability, estimated at 80% through linkage studies [4]; one of the most established genetic risk factors ...
  60. [60]
    Atopic dermatitis: a genetic-epidemiologic study in a ... - PubMed
    The pairwise concordance rate was 0.72 in monozygotic and 0.23 in dizygotic twin pairs. Conclusion: The frequency of atopic dermatitis is still increasing ...
  61. [61]
    Twin Studies of Atopic Dermatitis: Interpretations and Applications in ...
    Sep 2, 2015 · Particularly, the concordance rate of AD is consistently higher for monozygotic (MZ) than for dizygotic (DZ) twins [13], indicating that ...
  62. [62]
    Association of IL-4 and ADAM33 gene polymorphisms with asthma ...
    The most prominent SNPs of IL-4 and ADAM33 are 589C>T and 400A>G, respectively. There are also controversial reports on the association of these SNPs with ...
  63. [63]
    Increased expression of ADAM33 and ADAM8 with disease ...
    ADAM33, a disintegrin and metalloproteinase 33 gene, has been identified as a risk factor for asthma and bronchial hyperresponsiveness and has been ...
  64. [64]
    Causes of epidermal filaggrin reduction and their role in the ...
    We surmise that AD only develops in those filaggrin-deficient subjects who are exposed to environmental triggers, such as low humidity, high-pH surfactants, ...
  65. [65]
    Homozygous FLG mutations lead to complete loss of filaggrin ...
    For example, different types of heat- ing systems (Schafer et al. , 1999) and low-humidity environments are likely to exacerbate the effects of filaggrin ...<|control11|><|separator|>
  66. [66]
    Environmental Changes, Microbiota, and Allergic Diseases - PMC
    The development of allergic diseases has been attributed to complex interactions between environmental factors and genetic factors.
  67. [67]
    Con: House Dust Mites in Atopic Diseases - ATS Journals
    In 1964, Voorhorst and colleagues discovered that dust mites are the major source of allergen in house dust (1) and proposed an association between these mites ...
  68. [68]
  69. [69]
    Environmental Triggers of Asthma - CDC Archive
    Household exposures to dust mites and cockroach allergens, and the irritant effects of environmental tobacco smoke, contribute significantly to asthma ...Missing: PM2. | Show results with:PM2.
  70. [70]
    Long-term exposure to PM2.5 has significant adverse effects on ...
    Nov 15, 2024 · We demonstrate that long-term exposure to PM 2.5 significantly increases asthma risk in both children and adults and is associated with 30% asthma cases ...Missing: irritants atopy smoke
  71. [71]
    The hygiene hypothesis: current perspectives and future therapies
    Strachan proposed that this increased microbial exposure in early life could protect children from developing immune hypersensitivities later in life. Strachan ...
  72. [72]
    Interactions Between Atopic Dermatitis and Staphylococcus aureus ...
    Staphylococcus aureus commonly colonizes the skin of atopic dermatitis (AD) patients and contributes to the development and exacerbation of AD.
  73. [73]
    Environmental risk factors and their role in the management of ...
    Environmental risk factors for atopic dermatitis include prenatal exposures, irritants, climate, pollutants, tobacco smoke, water hardness, urban vs. rural ...
  74. [74]
    Atopic Sensitization and the International Variation of Asthma ...
    Jul 21, 2006 · The prevalence of asthma symptoms has been shown to vary more than 15-fold among countries worldwide. The international variation in the ...METHODS · RESULTS · DISCUSSION
  75. [75]
    Sex-Specific and Long-Term Trends of Asthma, Allergic Rhinitis, and ...
    Sep 16, 2024 · Conclusions: Throughout all the periods examined, females consistently exhibited a higher prevalence of AR compared to males. Moreover, the risk ...
  76. [76]
    The prevalences of allergic diseases in rural and urban areas are ...
    The prevalence of asthma was found as 11.5%, allergic rhinitis as 22.1%, and eczema as 10.7%. Asthma (21.9%), allergic rhinitis (44.3%) and eczema (19.8 ...
  77. [77]
    Do socioeconomic factors impact atopic dermatitis outcome? A ...
    Oct 10, 2023 · Race and socioeconomic status are thought to influence the severity of atopic dermatitis (AD), but findings differ between countries and measures used.
  78. [78]
    Prevalence and risk factors for childhood asthma - BMC Pediatrics
    Jan 20, 2025 · After pooling all included studies, we noted that the overall prevalence of asthma in children was 10.2% (95% CI: 9.5-11.0%). The prevalence of ...
  79. [79]
    Pediatric Asthma - StatPearls - NCBI Bookshelf - NIH
    May 4, 2024 · Identify the symptoms and signs of pediatric asthma, including wheezing, coughing, shortness of breath, and chest tightness. Implement evidence- ...
  80. [80]
    Atopic dermatitis - Genetics - MedlinePlus
    Oct 1, 2017 · While atopic dermatitis is not always due to an allergic reaction, it is commonly associated with other allergic disorders: up to 60 percent of ...<|control11|><|separator|>
  81. [81]
    The increased prevalence of allergy and the hygiene hypothesis - NIH
    Allergic atopic disorders, such as rhinitis, asthma, and atopic dermatitis, are the result of a systemic inflammatory reaction triggered by type 2 T helper (Th2) ...
  82. [82]
    (PDF) Asthma prevalence in 1973, 1988 and 2003 - ResearchGate
    Aug 9, 2025 · The prevalence of reported wheeze in the last year rose during each 15 year period (9.8%, 15.2%, 19.7%), with an even steeper rise in reported ...
  83. [83]
    Western Lifestyle and Increased Prevalence of Atopic Diseases
    The more easily accessible and thus more "modern" and westernized coastal villages showed a significantly higher prevalence of habitants suffering from atopic ...
  84. [84]
  85. [85]
    National prevalence of atopic dermatitis in Korean adolescents from ...
    May 29, 2024 · However, the most significant decline in prevalence occurred after the COVID-19 pandemic began, with a smaller decline observed during the ...
  86. [86]
    Impact of COVID-19 pandemic on adults and children with atopic ...
    This review thus aims to systematically evaluate the impact of COVID-19 pandemic-driven changes on AD and FA care, focusing on (1) the impact on AD/FA incidence ...
  87. [87]
    The many faces of the hygiene hypothesis
    One mechanism frequently associated with the hygiene hypothesis is the skewing of the TH1/TH2 balance away from allergy-promoting TH2 cells toward TH1 cells.
  88. [88]
    Skin and oral intervention for food allergy prevention based on dual ...
    Regarding food allergy causation, the dual allergen exposure hypothesis proposes that oral allergen exposure leads to immune tolerance, whereas allergen ...
  89. [89]
    The Role of the Western Diet on Atopic Dermatitis - NIH
    Sep 7, 2023 · In recent decades, there has been a global increase in the prevalence of Western-style diets (WDs) in Europe. These diets include processed ...
  90. [90]
    Urbanisation and asthma in low-income and middle-income countries
    Jul 5, 2019 · Urbanisation has been associated with temporal and geographical differences in asthma prevalence in low-income and middle-income countries (LMICs).Missing: projections | Show results with:projections
  91. [91]
    Global, regional, and national burden of asthma and atopic ...
    We expect 275 million (224–330) asthma cases and 148 million (140–158) atopic dermatitis cases in 2050, with population growth driving this increase.Missing: urbanization | Show results with:urbanization
  92. [92]
    None
    ### Key Recommendations on Primary Prevention of Allergic Diseases
  93. [93]
    Maternal dietary antigen avoidance during pregnancy or lactation, or ...
    Prescription of an antigen avoidance diet to a high‐risk woman during pregnancy is unlikely to reduce substantially her child's risk of atopic diseases.
  94. [94]
    The effect of probiotics in the prevention of atopic dermatitis in children
    Apr 27, 2023 · In this study, the meta-analysis showed that probiotics can effectively prevent the occurrence of atopic dermatitis (AD).
  95. [95]
    Randomized Trial of Peanut Consumption in Infants at Risk for ...
    Feb 23, 2015 · The LEAP study showed that early oral introduction of peanuts could prevent allergy in high-risk, sensitized infants and in nonsensitized ...
  96. [96]
    Association of atopic dermatitis with smoking: A systematic review ...
    Tobacco exposure might be a modifiable risk factor for atopic dermatitis (AD). We examine the association between AD and exposure to tobacco smoke.Abstract · Table I · Discussion
  97. [97]
    Dust mite avoidance for the primary prevention of atopic dermatitis
    Dust mite avoidance strategies alone or in combination with additional allergen avoidance modalities do not decrease the risk of developing atopic dermatitis.
  98. [98]
    Cleaner air could prevent thousands of late-life eczema cases
    Oct 9, 2025 · The researchers estimate that almost 16% of late-life eczema cases could be prevented by cutting air pollution in the worst-affected areas. Only ...Missing: regulation public
  99. [99]
    BCG Vaccination in Early Childhood and Risk of Atopic Disease
    Conclusion. BCG vaccination in early childhood is associated with reduced risk of atopic disease, especially in developed countries.
  100. [100]
    Is it Possible to Prevent Atopic Dermatitis?
    Apr 2, 2023 · Methods of AD prevention examined in research have focused on improving the skin barrier through use of emollients and moisturizers, reducing exposure to ...What Does Prevention Mean In... · What Is Known About The... · Emollients
  101. [101]
    Pathogenesis of allergic diseases and implications for therapeutic ...
    Mar 24, 2023 · Current guidelines suggest a combined application of allergen avoidance, pharmacotherapy, and/or allergen-specific immunotherapy (AIT)29,30 ( ...
  102. [102]
    Environmental Remediation in the Treatment of Allergy and Asthma
    If avoidance of second-smoke is impossible, then using a HEPA filter may be a beneficial and sustainable environmental intervention. Endotoxin. Endotoxin is ...Missing: dietary elimination
  103. [103]
    The role of environmental allergen control in the management of ...
    Classroom HEPA filters were successful in significantly reducing airborne particles and allergens compared to sham (an air filtration system without a ...Missing: dietary | Show results with:dietary
  104. [104]
    Pre-asthma: a useful concept for prevention and disease ... - NIH
    Allergic asthma. Allergic asthma often begins in childhood as part of a collection of atopic disorders (atopic dermatitis, food allergy, allergic rhinitis) ...
  105. [105]
    Use of biologicals in allergic and type-2 inflammatory diseases ...
    Sep 7, 2020 · Conclusion: The use of biologicals for the treatment of bronchial asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and ...
  106. [106]
    Precision medicine reaching out to the patients in allergology - NIH
    Currently, treatment options for IgE-mediated allergic diseases such as allergic rhinitis, atopic dermatitis, allergic asthma, and food allergy typically ...
  107. [107]
    EAACI Allergen Immunotherapy User's Guide - PMC - PubMed Central
    AIT for AR can be administered either by the subcutaneous (SCIT) or by the sublingual (SLIT) route. Both SCIT and SLIT have been shown effective in allergic ...
  108. [108]
    Mapping the Treatment Journey of Children on Subcutaneous ... - NIH
    Oct 2, 2025 · Efficacy categories: Good (>70% symptom reduction), Moderate (30–70 ... Symptom Score; SLIT, sublingual immunotherapy. Data Sharing ...
  109. [109]
    Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib ...
    Apr 24, 2025 · Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: A review of abrocitinib, baricitinib, and upadacitinib. Drugs ...
  110. [110]
    Innovative microbial strategies in atopic dermatitis - PMC
    Jul 23, 2025 · Emerging systemic jak inhibitors ... Gut microbiota restoration through fecal microbiota transplantation: A new atopic dermatitis therapy.
  111. [111]
    Current insights and trends in atopic dermatitis and microbiota ...
    Jun 24, 2025 · Emerging trends from 2020 to 2024 focus on adult AD severity, prebiotics, and personalized interventions like fecal microbiota transplantation ( ...